Spondyloarthritis & psoriatic arthritis
An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial
Primary result · BASDAIResult — go to the resultANCOVA-estimated group difference −1.508Authors' conclusion
These findings support the potential of Axia as a safe and effective nonpharmacological intervention to further improve the state of care of patients with axSpA in addition to conventional anti-inflammatory pharmacotherapy.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) on stable pharmacotherapy186 completed
- Participants
- 200 patients
- Comparison
- Axia smartphone app vs standard of care
- Primary endpoint
- BASDAI
- Follow-up
- 12 weeks
Methodological detailsmonocentric, 1:1 randomisation, 12-week
- Monocentric
- 1:1 randomisation
- 12-week
Primary result
As reported in the abstract
ANCOVA-estimated group difference
−1.508
P < 0.001
Further findings
ASAS20 response · 12 weeks
P < 0.001
ASAS40 response · 12 weeks
P < 0.001
| Outcome | ANCOVA-estimated group difference | P value |
|---|---|---|
| BASFI · 12 weeksExceeding MCID threshold | −1.139 | P < 0.001 |
| ASQoL questionnaire · 12 weeksExceeding MCID threshold | −2.297 | P < 0.001 |
Original publication
An app-based nonpharmacological intervention improves patient-reported disease activity, functionality, and quality of life in patients with axial spondyloarthritis: a randomised controlled trial. Ann Rheum Dis. Published 13 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →